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In this issue of the Journal, Giovanni and colleagues
analyze 12 recent manuscripts which reported the outcome
of patients with pancreatic cancer who required portal vein
(PV) or superior mesenteric vein (SMV) resection at the
time of pancreaticoduodenectomy (PD).1 They conclude
that venous resection can be safely performed and should
be considered in appropriately selected patients. Fortner
first popularized vascular resection at the time of PD in
1973 when he proposed the use of ‘‘regional pancreatec-
tomy.’’2 However, this concept has remained controversial
for the following reasons:
1. Most physicians do not understand the difference
between the historical experience with regional pan-
createctomy and isolated tumor resection of the SMV,
PV or superior mesenteric–portal vein (SMPV) con-
fluence performed as part of a gross complete resection
of the primary tumor. Vascular resection at the time of
PD was initially performed in an attempt to improve
survival duration by performing an en bloc resection of
the pancreas and surrounding structures.2 This concept
of regional pancreatectomy involved the systematic
resection of major peripancreatic vascular structures
together with wide soft tissue clearance. Contrary to
the beliefs of Fortner and others, radical PD has not
been demonstrated to confer a survival benefit.3,4 Most
physicians and many surgeons assume that the nega-
tive experience with regional pancreatectomy also
applies to patients with isolated tumor extension that
involves a short segment of the SMV or PV.
2. The addition of vascular resection and reconstruction
to PD increases the complexity of the operation and is
not something that all pancreatic surgeons feel capable
of performing. This issue may be amplified by the
limited experience of many surgeons with the technical
aspects of vascular surgery and the potential for
perioperative death and major morbidity that exists
with pancreatic surgery for cancer.
3. The published data which examines vascular resection
as a prognostic factor for survival duration is of poor
quality. The majority of such reports (including those
analyzed by Giovanni and colleagues) did not contain a
description of the process used to differentiate complete
(R0/R1) from incomplete (R2) gross resections. Even in
those patients who may have undergone a complete
gross resection, most manuscripts failed to incorporate
prospective standardized pathologic evaluation and
reporting of the PD specimen to differentiate R0 from
R1 resections. This is a critically important consider-
ation because the intraoperative finding of venous
adherence to the tumor is often unexpected and the
surgeon may then attempt to separate the SMPV
confluence from the pancreatic head. When this maneu-
ver is unsuccessful, the surgeon is left with either a
grossly positive margin or an inadvertent venotomy.
Venous injury often results in uncontrolled hemorrhage
and the necessity for rapid removal of the tumor without
proper attention to the SMA dissection; it is easy to
appreciate how such cases may result in an R2 resection.
In patients with grossly incomplete resections, and
without any form of preoperative therapy, it is likely that
their poor survival is due to the persistent adenocarci-
noma at the SMA or celiac origin, not the presence of a
vascular reconstruction. In the absence of prospective
evaluation of the SMA margin (performed by very few
of the papers analyzed by Giovanni and colleagues),
reports of venous resection during PD are impossible to
interpret. Further, even if the SMA margin is assessed
accurately, the pathologist cannot differentiate an R2
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from an R1 resection; the surgeon’s operative note must
state whether or not a gross complete resection was
performed.5
What we do know about venous resection at the time of
PD:
1. There should be no biologic significance to tumor
abutment or invasion of the lateral wall of the SMPV
confluence (in comparison with tumor invasion of
second- or third-order branches of the SMV) as the
primary tumor has access to the systemic circulation
very early in the disease course before diagnosis.6,7
Such tumor abutment or invasion of the wall of the
SMV occurs due to continued growth of the primary
tumor and is a reflection of both the location of the
tumor within the pancreatic head and tumor size. This
occurs long after the primary tumor has had access to
the systemic circulation. In addition, the biologic
process of metastatic growth in distant organs is a
complex event more dependent on the genetic profile
of the primary tumor (and the host) rather than its size
or location within the pancreas.
2. The SMV and PV are not surrounded by nerve tissue.
In contrast, the visceral arteries including the celiac
axis, hepatic artery, and SMA are surrounded by the
autonomic nerves which innervate the gastrointestinal
tract. Pancreatic cancers are frequently characterized
by extrapancreatic infiltrative growth, perineural inva-
sion, and extension along the autonomic nerves. One
can often see tumor extension along the SMA or celiac
axis extending posteriorly to the aorta and this neural
invasion is thought responsible for the pain associated
with this disease. In such cases, resection of the
involved artery, if performed, may not clear the
posterior extent of disease, which may involve
the para-aortic autonomic ganglia. The visceral veins
such as the SMV or PV do not have an investing sheath
of autonomic neural tissue.
3. Circumferential skeletonization or segmental resection
of the SMA will deinnervate the small bowel and
frequently result in rapid gastrointestinal transit. In
patients of normal or thin body habitus this will cause
nutritional depletion and the need for total parenteral
nutrition. Such is not the case in patients who require
segmental resection of the SMV or PV.
4. In contrast to tumor–artery abutment, which can be
accurately interpreted on good-quality computed
tomography (CT) imaging, tumor abutment of the
lateral or posterolateral wall of the SMV or the SMPV
confluence may not always be appreciated on preop-
erative imaging. Because of this, surgeons without the
technical ability to perform venous resection may be in
the position of being unable to separate the SMV from
the tumor, predisposing to an incomplete resection or
an inadvertent venotomy. Importantly, deformity of
the vein wall at the tumor interface, even if subtle,
often indicates tumor adherence. This may be appre-
ciated only if the CT images are performed with a
venous phase of contrast enhancement and are accu-
rately interpreted.
5. When vascular resection and reconstruction is per-
formed by experienced surgeons at institutions where
such surgery is frequently performed, morbidity and
mortality are not increased compared with standard PD
without the need for vascular resection.5,8
Current recommendations for optimal clinical care and
clinical research:
1. Surgeons who perform PD should carefully review the
preoperative cross-sectional imaging studies and assess
the relationship of the low-density tumor to the
adjacent arteries (celiac, hepatic, SMA) and veins
(SMV, PV). Aberrant hepatic arterial anatomy should
be apparent on preoperative imaging and should not be
an unexpected finding at the time of laparotomy. The
relationship of the tumor to the SMPV confluence and
the presence or absence of a deformity in the contour
of the vein should alert the surgeon to the need for
venous resection. The anatomy of the SMV as related
to the location of the jejunal branch (with respect to the
SMA) and the anatomy of the inferior mesenteric vein
should also be identified on preoperative imaging.9
2. Surgeons who perform PD should have a strategy to
deal with unexpected venous adherence at the time of
surgery.
3. When the tumor cannot be separated from the SMV,
PV or SMPV confluence, a controlled venous resection
and reconstruction should be performed. We usually
use inflow occlusion on the SMA to prevent small
bowel edema which may complicate the pancreatic
and biliary reconstruction.8
4. The surgeon must document (in the operative dicta-
tion) the presence or absence of a complete gross
resection at the time of PD. The pathologist should
examine the PD specimen in conformity with College
of American Pathologists (CAP) or American Joint
Committee on Cancer (AJCC) guidelines which
include careful analysis of the SMA margin. Such
margin analysis should be performed irrespective of
whether or not vascular resection has been performed.
The current (6th) edition of the AJCC Staging Manual
emphasizes the importance of the R designation in all
pathology reports and for this disease (and the
operation of PD in particular) the operative dictation
and the pathology report must be integrated to develop
an accurate R designation.10 Manuscripts which assess
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vascular (usually venous) resection as a prognostic
factor for survival must include such a system for the
assessment of R status and their system must be
accurately described in the ‘‘Methods’’ section of the
manuscript.8
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